Medications are the first-line treatment for atrial fibrillation, or A-fib. When they begin to fail, one option is ablation.

The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.

Profound Medical Corp. ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased ...

Dr. Nassir Marrouche is director of the Heart and Vascular Institute at Tulane University with a subspecialty in ...

DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced positive results from its Phase 1 multiple ascending dose (MAD) study of ...

This review highlights the potential of natural polysaccharide microneedles in cancer immunotherapy, focusing on localized ...

The Sapien M3 transcatheter mitral valve replacement system won FDA approval -- making it the first on the market to utilize ...

By way of a story, of course. Happy 2026 to you and yours. Stress eating an entire bag of harvest cheddar Sun chips and ...

Taking a 30-day break from drinking alcohol can provide several health benefits. Among the biggest benefits, your risk of cancer and heart disease may decrease. You may also experience improved sleep ...

Denatured alcohol is an ingredient often found in cleaning or cosmetic products. Keeping denatured alcohol away from open flames prevents fires, as it's highly flammable. Storing denatured alcohol in ...

Objective Patients with atrial fibrillation (AF) frequently have multiple comorbidities that increase the risk of hospitalisation and contribute to higher mortality. However, studies examining the ...